Assembly Biosciences has evolved into a well-funded antiviral development platform, supported by a strategic partnership with Gilead and a strong balance sheet. Its pipeline targets diseases with high unmet needs such as recurrent genital herpes, HDV, and cholestatic liver diseases, showing promising early clinical data. With over $340 million in pro forma liquidity after a recent offering, the company can fund operations through 2028 without needing near-term capital. Despite these strengths and upcoming Phase 2/3 catalysts, Assembly Biosciences trades at a valuation discount compared to peers.
US spot Bitcoin ETFs experienced a $389.71 million outflow last week, the largest in six weeks, reversing the previous week's $853.54 million inflow. Ethereum ETFs also saw a $2.26 million outflow, breaking a five-week streak of inflows. Despite thes...
Shanghai Henlius Biotech has formed a strategic collaboration with Sandoz to develop and commercialize up to 10 monoclonal antibody and antibody-drug conjugate biosimilars globally, excluding China. The partnership builds on their 2025 oncology biosi...
Euro Manganese has signed a non-binding offtake term sheet with U.S.-based 6K Energy to supply high-purity electrolytic manganese metal from its Chvaletice Project in the Czech Republic, starting in 2028. 6K Energy has successfully tested and prelimi...
Impact Fusion International (IFUS) has installed a retrofitted Selco/Mosley Badger Double Ram Press to increase production capacity and efficiency at its Napoleonville, Louisiana facility. The new machine allows IFUS to produce up to 600 bales per da...
Uniswap's UNI token price fell 18% this week, the worst among the top 100 cryptocurrencies, despite large holders (whales) withdrawing UNI from Binance at the fastest rate in five years. This suggests whales are accumulating rather than selling, even...
